WuXi AppTec offers a comprehensive platform to evaluate lead candidates targeting various types of pain, including inflammatory, neuropathic, and fibromyalgia-like pain and osteoarthritis. Our expertise and experience allow us to offer an extensive portfolio of services supporting drug discovery and development, from target discovery to translational research and clinical biomarker testing and beyond. Full-scale molecular …Read More >

Delivering comprehensive end-to-end solutions for creating, identifying, and supporting preclinical candidates, from discovery to development, with our integrated chemistry and biology research platforms.  

Download our whitepaper on how using biophysical techniques can enhance and streamline processes throughout the drug discovery and validation cycle. Discover fresh opportunities to characterize challenging drug targets, examine biophysical screening methods, and look toward what’s next for biophysical methods in drug discovery.

Abstract Antibody drug conjugates (ADCs) are promising complexes with therapeutic potential that aimed to the treatment of solid tumor and hematological malignancies. Compared with the therapeutic monoclonal antibody, an ADC-derived monoclonal antibody is conjugated with cytotoxic agents (payloads) which can deliver potent cellular toxins to targeted cancer cells specifically. We have established a state-of-the-art platform …Read More >

In vitro Biology Services |  Early in vitro safety panel – Assays and Data Summary Functional Assays Radio ligand binding Assays

WuXi AppTec  | Target-to-Hit Solutions Protein Production  | All Target Classes and Challenging Proteins Biophysical & Biochemical Platforms |  Ready-To-Go Assay for Broad Range of Drug Targets Structural Biology Platforms Covalent and non-covalent fragment libraries & Screening